Sudan Virus

Sudan virus (SUDV) is a member of the Ebola virus genus in the family Filoviridae and is one of the main pathogens causing severe Ebola virus disease (EVD) in humans. It was first discovered in June 1976 when it erupted simultaneously in Nzara, South Sudan, and has since caused multiple outbreaks, mainly concentrated in Uganda and Sudan. The characteristic of SUVV is its high mortality rate. In past epidemics, the mortality rate ranged from 41% to 70%, with an average of about 50%. This makes it the second most pathogenic Ebola virus after Ebola virus (EBOV). Unlike EBOV, which has already developed vaccines and treatments, there is currently no licensed vaccine or specific treatment for Sudan Virus Disease (SVD), highlighting a key gap in global health preparedness. Due to its high lethality and potential use in bioterrorism, the virus is classified as a Class A priority pathogen and therefore requires ongoing research and monitoring efforts.

Figure 1.Structure of Sudan Virus.( Dias, João M., et al.2011)

Infection Mechanism

SudV enters the host cell through two steps: it attaches to the host receptor Niemann Pick C1 (NPC1), and then the viral envelope fuses with the endosomal membrane. NPC1 is a cholesterol transporter located in the endosome and is the primary entry receptor for all pathogenic Ebola viruses. Cryo electron microscopy studies have shown that the GP₁ subunit of SudV binds to the cysteine rich domain 1 of NPC1, and the four amino acid differences (compared to Ebola virus) explain its enhanced binding affinity. This increased affinity may contribute to the effective cellular tendency and high mortality rate of SudV. Once inside the cell, the RNP complex is released into the cytoplasm, where the virus replicates and transcribes. The newly synthesized viral protein and genome are assembled on the plasma membrane, and VP40 mediates the budding of progeny viral particles, which then infect adjacent cells. The Anti-SUDV GP polyclonal antibody can target the GP₁ subunit to study its binding with NPC1, while the Human Anti-Sudan Ebola Virus Glycoprotein (SUDV-GP) IgG ELISA Kit enables quantification of anti-SUDV-GP IgG to assess immune responses related to this infection process.

Key Molecular Targets for Therapeutics and Vaccines

Due to the lack of approved SVD treatment methods, research on therapeutic interventions targeting specific viral components has been accelerated.

Clinical Manifestations

The incubation period of SUVV is 2 to 21 days, after which patients may suddenly experience non-specific symptoms. This disease is usually divided into two stages:

• Whole body phase: Initial symptoms include sudden high fever, severe headache, muscle pain, joint pain, and extreme fatigue. Subsequently, gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain usually occur.
• Bleeding and neurological phase: In severe cases, the disease can develop into manifestations of hemorrhagic fever, which may include unexplained mucosal bleeding, bruising, and internal bleeding. Patients may also experience encephalitis or other neurological symptoms. Multiple organ failure, disseminated intravascular coagulation (DIC), and septic shock typically occur before death, usually in the second week of illness.

The mortality rate is high, and survivors may experience long-term sequelae such as arthritis, eye disease, and hearing loss.

Eastern Equine Encephalitis Virus Antibody

Eastern Equine Encephalitis Virus Antigens